Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients

[1]  B. Wullich,et al.  Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. , 2004, The Journal of urology.

[2]  A. Hanlon,et al.  The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer , 2004, Cancer.

[3]  Joseph A. Smith,et al.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 , 2003 .

[4]  E. Horwitz,et al.  Treatment of prostate cancer with regional lymph node (N1) metastasis. , 2003, Seminars in radiation oncology.

[5]  S. Campbell,et al.  Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. , 2002, International journal of radiation oncology, biology, physics.

[6]  A. Markoe,et al.  Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). , 2002, International journal of radiation oncology, biology, physics.

[7]  Juni Palmgren,et al.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2002, The New England journal of medicine.

[8]  V. Hasselblad,et al.  Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma , 2002, Cancer.

[9]  U. Vaishampayan,et al.  The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century. , 2002, Critical reviews in oncology/hematology.

[10]  Neil Fleshner,et al.  Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. , 2002, The Journal of urology.

[11]  A. Heidenreich,et al.  Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. , 2002, The Journal of urology.

[12]  A. V. von Eschenbach,et al.  Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. , 2001, Urology.

[13]  D. Grignon,et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[14]  K. Griffith,et al.  Definitions of biochemical failure in prostate cancer following radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[15]  M. Gleave,et al.  Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. , 2000, Urology.

[16]  P. Walsh.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 2000, The Journal of urology.

[17]  E. Bergstralh,et al.  Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. , 1999, The Journal of urology.

[18]  M. Soloway,et al.  Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. , 1998, The Journal of urology.

[19]  B. Chauvet,et al.  [Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin]. , 1998, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[20]  M. Blute,et al.  Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. , 1998, The Journal of urology.

[21]  H. Zincke,et al.  Radical prostatectomy and early adjuvant hormonal therapy for pTxN+ adenocarcinoma of the prostate. , 1997, Urology.

[22]  S B Malkowicz,et al.  The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[23]  H. Sandler,et al.  Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[24]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[25]  S. Fosså,et al.  Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage t0 to 4,N1 to 3.M0,D1). European Organization for Research and Treatment of Cancer Genitourinary Group. , 1995, The Journal of urology.

[26]  H. Sandler,et al.  Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. , 1995, International journal of radiation oncology, biology, physics.

[27]  K. Wallner,et al.  Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Bergstralh,et al.  Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors , 1992, Cancer.

[29]  W. Sause,et al.  Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. , 1988, International journal of radiation oncology, biology, physics.

[30]  Gleason Df.  Classification of prostatic carcinomas. , 1966 .

[31]  Ma Sheng-lin.  Three-dimensional conformal radiotherapy for brain gliomas , 2005 .

[32]  C. Zippe,et al.  Variable definitions influence the reporting of biochemical failure rates , 2002, Prostate Cancer and Prostatic Diseases.

[33]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[34]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[35]  A. Markoe,et al.  Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. , 2000, International journal of radiation oncology, biology, physics.

[36]  A. Zietman,et al.  The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. , 1997, The cancer journal from Scientific American.

[37]  M. Wirth,et al.  Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone. , 1995, European urology.

[38]  A. Pollack,et al.  Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. , 1995, International journal of radiation oncology, biology, physics.

[39]  M. Zelefsky,et al.  The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. , 1994, International journal of radiation oncology, biology, physics.